Brillance Ventures

Brilliance Ventures is an Israeli venture capital fund founded in 2018 and headquartered in Tel Aviv. The firm invests in core technology companies at growth stages — specifically AI, machine learning, medical technology, and deep tech — deploying $100,000 to $5 million per investment with a sweet spot around $1.5 million. The portfolio spans 15 companies. Co-founded by Keren Maimon (Managing Partner) and Qian Chen (China-based Partner), Brilliance was built around an explicit cross-border mandate: connecting Israeli tech startups with capital and partnerships in China's largest companies. The firm executes investment banking activities alongside its fund operations, including fundraising, mergers and acquisitions, private placements, secondary deals, and IPOs from Asia. This dual capability — fund investment plus deal-structuring expertise — gives portfolio companies access to Chinese corporate buyers and strategic partners at a stage when such relationships are otherwise difficult for Israeli founders to cultivate directly. Investment stages are Series A and Series B. Brilliance's value proposition rests on the observation that Israeli technology, particularly in AI, medtech, and hardware, commands significant strategic interest from Asian acquirers and growth investors — but that most Israeli founders lack the relationships and local knowledge to convert that interest into capital or partnerships. The firm fills that gap through direct China-based representation and a decade of relationship-building across both ecosystems.